ERBB2 and breast cancer: The DESTINY-Breast04 study (NCT03734029) showed a superior PFS with T-Dxd to the investigator’s choice chemotherapy in HR+/HER2-low breast cancer with at least two lines of endocrine therapy in a metastatic setting [31,32].